Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 45

Sort by

Sort Order Select

Journal Articles

A Phase I First-in-Human, Open-Label Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0500, a Humanized GPRC5D-BCMA-CD3 Trispecific Antibody, in Participants with Relapsed or Refractory Multiple Myeloma

Yan Xu, Zhen Cai, Zhongjun Xia, Chen Yang, Jia Chen, Zewen Zhu, Xiaojuan Jing, Ji Tian, Nating Zhang, Ailing Cui, Jianxing Tang, Haolin Sun, Lugui Qiu

Blood (2024) 144 (Supplement 1): 3381.2.

https://doi.org/10.1182/blood-2024-200737

Published: 2024

Journal Articles

Safety and Efficacy of Selinexor Plus Bortezomib, Lenalidomide and Dexamethasone (XVRd) in High Risk Newly Diagnosed Multiple Myeloma: A Multi-Center, Single-Arm, Phase Ib/II Trial

Xiaoqin Chen, Yun Wang, Weida Wang, Hua Wang, Bingyi Wu, Yang Liang, Zhongjun Xia

Blood (2024) 144 (Supplement 1): 7025.

https://doi.org/10.1182/blood-2024-204564

Published: 2024

Journal Articles

Carfilzomib, Pomalidomide, Dexamethasone with and without Daratumumab in Relapsed/Refractory Multiple Myeloma: A Multi-Center, Prospective Real World Study in China

Fujing Zhang, Wei Wang, Hua Wang, Wei Wang, Aijun Liu, Weiwei Tian, Xiaoqi Qin, Zhongjun Xia, Junling Zhuang

Blood (2024) 144 (Supplement 1): 6985.

https://doi.org/10.1182/blood-2024-209342

Published: 2024

Journal Articles

Monitoring the Signs and Symptoms of Variant Creutzfeldt-Jakob Disease Among Patients with Multiple Myeloma Treated with Ixazomib Capsules in China: A Real-World Pharmacovigilance Survey

Zhongjun Xia, Lin Li, Sha Liu

Blood (2024) 144 (Supplement 1): 6969.

https://doi.org/10.1182/blood-2024-202985

Published: 2024

Journal Articles

Isatuximab Plus Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Versus Vrd in Chinese Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplant: IMROZ Subgroup Analysis

Gang An, Zhuogang Liu, Jie Jin, Zhen Cai, Wei Li, Zhongjun Xia, Xinan Cen, Yu Hu, Jian-Qing Mi, Hongmei Jing, Rong Zhan, Xiaoyan Qu, Xin Du, Dan Gao, Liang Zhao, Lugui Qiu

Blood (2024) 144 (Supplement 1): 7055.

https://doi.org/10.1182/blood-2024-199908

Published: 2024

Journal Articles

Clinical Outcome of Induction Treatment in the Era of Novel Agents and the Impact of the Number of High-Risk Cytogenetic Abnormalities (HRA) on Prognosis of Patients with Newly Diagnosed Multiple Myeloma (NDMM): Insights from a Multi-Center Study

Dong Liang, Demei Feng, Qiaoli Wang, Shenrui Bai, Min Zeng, Bo Lu, Xiaoqing Li, Zhiqiang Sun, Jianyun Li, Huanhuan Zhou, Jialu Zhang, Xiaoqin Chen, Zhongjun Xia, Yang Liang, Hua Wang

Blood (2024) 144 (Supplement 1): 7064.

https://doi.org/10.1182/blood-2024-204519

Published: 2024

Journal Articles

Lactate Metabolism-Related Genes to Predict the Clinical Outcome and Molecular Characteristics of Multiple Myeloma

Lingling Shu, Ziang Zhu, Yang Li, Hanying Huang, Xiaoqin Chen, Zhongjun Xia, Yang Liang

Blood (2024) 144 (Supplement 1): 4693.

https://doi.org/10.1182/blood-2024-207432

Published: 2024

Journal Articles

Initial Results from a Phase 1 Study of TQB2934, a BCMA × CD3 Bispecific Antibody, As Monotherapy in Patients with Relapsed/Refractory Multiple

Peng Liu, Junling Zhuang, Zhongjun Xia, Bingzong Li, Songfu Jiang, Yian Zhang, Wei Wang, Xiaoqin Chen, Xiaohui Zhang, Shujuan Zhou

Blood (2024) 144 (Supplement 1): 1998.

https://doi.org/10.1182/blood-2024-209665

Published: 2024

Journal Articles

Subgroup Analyses of Phase 2 Study: Evaluating the Efficacy of Fully Human BCMA-Targeting CAR T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 4762.

https://doi.org/10.1182/blood-2024-204620

Published: 2024

Journal Articles

Weekly Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase 3 Bench Study

Blood (2024) 144 (Supplement 1): 4748.

https://doi.org/10.1182/blood-2024-202893

Published: 2024

Journal Articles

Monitoring the Sign & Symptoms of Variant Creutzfeldt-Jakob Disease Among Patients with Multiple Myeloma Treated with Ixazomib Capsules in China: A Real-World Pharmacovigilance Survey

Zhongjun Xia, Xiaolin Xia, Lin Li, Sha Liu

Blood (2023) 142 (Supplement 1): 6629.

https://doi.org/10.1182/blood-2023-179108

Published: 2023

Journal Articles

MM-SZ01 Study: A Prospective, Randomized, Controlled, Multicenter Phase III Clinical Study Which Compared Polyethylene Glycol Liposomal Doxorubicin Versus Doxorubicin Combined with Bortezomib and Dexamethasone (PDD regimen vs PAD regimen) in the Treatment of Newly Diagnosed Multiple Myeloma in China

Qingqing Wang, Depei Wu, Chengcheng Fu, Shuang Yan, ChengHao Jin, Xuzhang Lu, Tao Chen, Fei Li, Zhongjun Xia, Bingzhong Li

Blood (2022) 140 (Supplement 1): 12614–12615.

https://doi.org/10.1182/blood-2022-159065

Published: 2022

Journal Articles

Real-World Outcome of Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma: A Multicenter Propensity Score Matched Case Series Study

Weida Wang, Yaofang Hu, Yun Wang, Xiaoqin Chen, Zhongjun Xia

Blood (2022) 140 (Supplement 1): 12589–12590.

https://doi.org/10.1182/blood-2022-171132

Published: 2022

Journal Articles

Ixazomib, Lenalidomide, and Dexamethasone (IRd) Versus Ixazomib, Pegylated Liposomal Adriamycin, and Dexamethasone(IDd) in Elderly Frail Newly Diagnosed Multiple Myeloma with GA Score ≥2: A Prospective Multicenter Study

Li Bao, Min-qiu Lu, Peng Liu, Yu-Tong Wang, Junling Zhuang, Mei Zhang, Zhongjun Xia, Zhenling Li, Ying Yang, Zhenyu Yan, Hongmei Jing, Wenming Chen, Hebing Zhou, Rong Fu, Yuping Gong, Wenrong Huang, Yongqing Zhang

Blood (2022) 140 (Supplement 1): 12564–12565.

https://doi.org/10.1182/blood-2022-168068

Published: 2022

Journal Articles

Phase Ⅱ Study of Fully Human BCMA-Targeting CAR-T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma

Blood (2022) 140 (Supplement 1): 4564–4565.

https://doi.org/10.1182/blood-2022-168610

Published: 2022

Journal Articles

Identification of a Novel Drug Sensitivity Biomarker Neuregulin-2 for Venetoclax in Non-t(11;14) Multiple Myeloma

Yujun Dai, Xue-Ping Li, Fang Hu, Jinyuan Li, Yang Liang, Da-Wei Wang, Zhongjun Xia, Xiaoqin Chen

Blood (2021) 138 (Supplement 1): 459.

https://doi.org/10.1182/blood-2021-150370

Published: 2021

Journal Articles

Orelabrutinib Monotherapy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Updated Long Term Results of Phase II Study

Blood (2021) 138 (Supplement 1): 2638.

https://doi.org/10.1182/blood-2021-146491

Published: 2021

Journal Articles

Ixazomib Based Maintenance Therapy for the Patients with Newly Diagnosed Multiple Myeloma in Real-World Practice

Blood (2021) 138 (Supplement 1): 2718.

https://doi.org/10.1182/blood-2021-149058

Published: 2021

Journal Articles

Phase 2 March Study: ATG-010 Plus Low Dose Dexamethasone in Chinese Relapsed/Refractory Multiple Myeloma (RRMM) Patients Previously Treated with an Immunomodulatory Agent (IMiD) and a Proteasome Inhibitor (PI)

Blood (2021) 138 (Supplement 1): 4770.

https://doi.org/10.1182/blood-2021-145282

Published: 2021

Journal Articles

ATG-010 Plus Low-Dose Dexamethasone (Sd) in Chinese Relapsed/Refractory Multiple Myeloma (RRMM) Patients Previously Received Chimeric Antigen Receptor T-Cell (CAR-T)

Blood (2021) 138 (Supplement 1): 4778.

https://doi.org/10.1182/blood-2021-146784

Published: 2021

NARROW

A Phase I First-in-Human, Open-Label Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0500, a Humanized GPRC5D-BCMA-CD3 Trispecific Antibody, in Participants with Relapsed or Refractory Multiple Myeloma

Safety and Efficacy of Selinexor Plus Bortezomib, Lenalidomide and Dexamethasone (XVRd) in High Risk Newly Diagnosed Multiple Myeloma: A Multi-Center, Single-Arm, Phase Ib/II Trial

Carfilzomib, Pomalidomide, Dexamethasone with and without Daratumumab in Relapsed/Refractory Multiple Myeloma: A Multi-Center, Prospective Real World Study in China

Monitoring the Signs and Symptoms of Variant Creutzfeldt-Jakob Disease Among Patients with Multiple Myeloma Treated with Ixazomib Capsules in China: A Real-World Pharmacovigilance Survey

Isatuximab Plus Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Versus Vrd in Chinese Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplant: IMROZ Subgroup Analysis

Clinical Outcome of Induction Treatment in the Era of Novel Agents and the Impact of the Number of High-Risk Cytogenetic Abnormalities (HRA) on Prognosis of Patients with Newly Diagnosed Multiple Myeloma (NDMM): Insights from a Multi-Center Study

Lactate Metabolism-Related Genes to Predict the Clinical Outcome and Molecular Characteristics of Multiple Myeloma

Initial Results from a Phase 1 Study of TQB2934, a BCMA × CD3 Bispecific Antibody, As Monotherapy in Patients with Relapsed/Refractory Multiple

Subgroup Analyses of Phase 2 Study: Evaluating the Efficacy of Fully Human BCMA-Targeting CAR T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma

Weekly Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase 3 Bench Study

Monitoring the Sign & Symptoms of Variant Creutzfeldt-Jakob Disease Among Patients with Multiple Myeloma Treated with Ixazomib Capsules in China: A Real-World Pharmacovigilance Survey

MM-SZ01 Study: A Prospective, Randomized, Controlled, Multicenter Phase III Clinical Study Which Compared Polyethylene Glycol Liposomal Doxorubicin Versus Doxorubicin Combined with Bortezomib and Dexamethasone (PDD regimen vs PAD regimen) in the Treatment of Newly Diagnosed Multiple Myeloma in China

Real-World Outcome of Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma: A Multicenter Propensity Score Matched Case Series Study

Ixazomib, Lenalidomide, and Dexamethasone (IRd) Versus Ixazomib, Pegylated Liposomal Adriamycin, and Dexamethasone(IDd) in Elderly Frail Newly Diagnosed Multiple Myeloma with GA Score ≥2: A Prospective Multicenter Study

Phase Ⅱ Study of Fully Human BCMA-Targeting CAR-T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma

Identification of a Novel Drug Sensitivity Biomarker Neuregulin-2 for Venetoclax in Non-t(11;14) Multiple Myeloma

Orelabrutinib Monotherapy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Updated Long Term Results of Phase II Study

Ixazomib Based Maintenance Therapy for the Patients with Newly Diagnosed Multiple Myeloma in Real-World Practice

Phase 2 March Study: ATG-010 Plus Low Dose Dexamethasone in Chinese Relapsed/Refractory Multiple Myeloma (RRMM) Patients Previously Treated with an Immunomodulatory Agent (IMiD) and a Proteasome Inhibitor (PI)

ATG-010 Plus Low-Dose Dexamethasone (Sd) in Chinese Relapsed/Refractory Multiple Myeloma (RRMM) Patients Previously Received Chimeric Antigen Receptor T-Cell (CAR-T)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only